Leading the Way in Life Science Technologies

GEN Exclusives

More »

Columns

More »
Mar 15, 2009 (Vol. 29, No. 6)

Novel OncoMouse Model

  • Caliper Discovery Alliances & Services (CDAS), which offers multiple tumor models for preclinical cancer research, reports that it recently developed a pancreatic OncoMouse® model—EL1-luc/EL1-SV40 T-antigen transgenic—to overcome some disadvantages of xenograft tumor models, such as the use of immuno-compromised mice. Through a specific agreement with DuPont Intellectual Assets & Licensing (see January 1 GEN, page 16), CDAS says it can now provide preclinical in vivo compound efficacy and research studies using spontaneous tumor models linking an activated oncogene with a bioluminescent reporter system. It is now possible for scientists to study drug effects in the more relevant physiological microenvironment context of a nonimmnuno-compromised animal, which will better recapitulate the effect of the drug in humans, according to a CDAS official.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »